Senesco Technologies Inc. (SNT: Quote) announced the results from the completed non-clinical study of SNS01-T in combination of lenalidomide in a model of multiple myeloma. Combining SNS01-T treatment with lenalidomide, or (the active ingredient in REVLIMID marketed by Celgene Corporation, inhibits tumor growth more effectively than either drug alone.
All mice treated with the combination survived over 100 days to the end of the study. Tumors were eradicated after a single 6-week cycle of the combination in two thirds of the animals, and there was no regrowth after an additional 8 weeks without further treatment, the company said.
Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells.
Click here to receive FREE breaking news email alerts for Senesco Technologies Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com